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Serum ferritin is an independent predictor of histologic severity 
and advanced fibrosis in patients with nonalcoholic fatty liver 
disease.
Kris V. Kowdley, Patricia Belt, Laura A Wilson, Matthew M. 
Yeh, Brent A. Neuschwander-Tetri, Naga Chalasani, Arun J. 
Sanyal, and James E. Nelson; for the NASH Clinical Research 
Network. Hepatology 2012;55:77-85.
Nonalcoholic fatty liver disease (NAFLD) is now 
recognized as a major cause of chronic liver diseases, 
including liver cirrhosis and hepatocellular carcinoma 
(HCC) in Western countries.
1,2 Like alcoholic liver disease, 
NAFLD covers a wide spectrum of disorders from simple 
steatosis to nonalcoholic steatohepatitis (NASH) and 
cirrhosis. Approximately 30% of the US population and 
20% of the Korean population have NAFLD.
1,3
Just as all heavy drinkers do not progress to cirrhosis 
and HCC, nor do all patients with nonalcoholic steatosis 
progress. In addition to its high prevalence, one of the 
challenges facing hepatologists is the diagnosis and risk 
stratification of NAFLD. There is no proven serologic 
marker to confirm the disease, which is diagnosed by 
excluding a history of alcohol consumption and other 
causes of liver disease using various serologic tests; some-
times a liver biopsy is needed. Moreover, after the diag-
nosis, it is not clear who will progress to cirrhosis or HCC. 
Central obesity is a well-known risk factor and hyper-
glycemia, diabetes, and age are associated with advanced 
fibrosis.
1,4 However, to evaluate the risk of disease pro-
gression, a liver biopsy is essential. Recently non-invasive 
methods to distinguish between simple steatosis and 
significant fibrosis have been introduced. Serological tests 
have been investigated, including α2-macroglobulin, apoli-
poprotein A-I, hyaluronic acid, the platelet count, bilirubin, 
and gamma-glutamyl transpeptidase.
2 Direct and indirect 
inflammation mediators such as interleukin-6 (IL-6), 
CC-chemokine ligand 2, and N-glycans gave positive 
results, but further studies are needed to determine whether 
these have diagnostic roles.
2 An apoptosis product, cytoker-
atin-18 (CK-18) fragments, was also associated with NASH 
or fibrosis.
5
Recently, hepatic iron overload and its correlation with 
chronic liver disease have been considered.
6,7 With recent 
progress in understanding iron metabolism in patients with 
hereditary hemochromatosis at the molecular level, accumu-
lating evidence suggests a link between altered iron metabo-
lism and NAFLD. In the last decade, many studies have 
found a relationship between hepatic iron and NASH or its 
progress.
8-11
Iron (ferrum in Latin), atomic number 26, is the most 
common element on Earth. It is essential in most living 
organisms. Iron binds to cofactors in hemes, myoglobin, 106  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
cytochrome P450, and catalases. When body iron accumulates, 
it promotes oxidative free-radical reactions, which have 
harmful effects. In hereditary hemochromatosis, accumulated 
iron in the liver, heart, and pancreas leads to cirrhosis, heart 
failure, and diabetes. Even mild iron overload might aggravate 
insulin resistance, diabetes, atherosclerosis, colonic neoplasia, 
and NAFLD.
6,12-15 Moreover, iron depletion therapy, such as 
with a phlebotomy, improves the metabolic complications 
and elevated liver enzymes in patients with NAFLD.
16 Iron 
is strictly regulated by a mechanism similar to that for 
glucose control.
17 Like glucose and insulin, the serum iron 
level is regulated by a hepatic peptide hormone, hepcidin. 
An elevated iron level stimulates hepcidin synthesis, which 
decreases the iron-exporter ferroportin in macrophages 
and intestinal cells and reduces serum iron, just as insulin 
controls excess glucose.
17,18 Currently, people in developed 
countries consume an overabundance of food. Since most 
food contains glucose and iron, excessive eating can increase 
the risks of hyperglycemia and iron overloading. Since 
accumulated iron is difficult to remove, males and the 
elderly are at higher risk for iron accumulation than females 
and younger people. Females lose body iron via regular 
menstruation. This “iron-theory” may explain the gender 
difference in cardiovascular diseases, although it has not 
been confirmed whether iron has the same effects on chronic 
liver diseases.
19
Kowdley et al
20 investigated the serum ferritin level and 
histological findings, including iron deposition, in 628 
patients with NAFLD. This large cross-sectional study 
revealed that an elevated serum ferritin (>1.5×UNL) was 
associated with advanced hepatic fibrosis (odds ratio [OR], 
1.66; 95% confidence interval [CI], 1.05-2.62; P=0.028) and 
a higher NAFLD Activity Score (NAS) (OR, 1.99; 95% CI, 
1.06-3.75; P=0.033). An elevated serum ferritin (seen in 
approximately 20% of the subjects) was associated with 
greater iron accumulation in the body (i.e., a high serum iron 
and transferrin-iron saturation) and greater hepatic iron 
deposition in both the reticuloendothelial system and 
hepatocytes. The patients with an increased serum ferritin 
also had higher serum transaminases and gamma-glutamyl 
transferase, and a lower platelet count. Interestingly, even in 
patients without a hepatic iron overload on histology, a 
higher serum ferritin was correlated with an advanced stage. 
This suggests the presence of systemic inflammation 
unrelated to iron overload. There are a few contradictory 
reports on the role of the iron burden in patients with 
NAFLD.
21,22 It is not clear whether the elevated serum 
ferritin is a consequence of systemic inflammation or a 
marker of iron overload in patients with NAFLD. The study 
by Kowdley et al
20 seems to keep to the middle path. I would 
like to know more about the proportion of patients who had 
an elevated serum ferritin, but no iron deposition, in their 
study. Further studies to confirm the role of iron in NAFLD 
are needed.
Should we use this simple, sensitive, and inexpensive test 
in all patients with NAFLD? Before approving its clinical 
use, one should consider the fact that most of the subjects in 
this study were severely obese (average BMI 34 kg/m
2) and 
had metabolic syndrome (69%). The study population might 
differ from the real general population. In less-obese 
populations, the serum ferritin might differ and the iron 
burden might not be complicated. The cut-off level for the 
serum ferritin (1.5×UNL) in this study was subjective and 
needs further supporting data.
In summary, not all patients with NAFLD progress to 
cirrhosis or HCC. It is not clear what factor(s) contribute to 
advanced liver disease. Dysregulated iron overload might be 
a contributing factor. Serum ferritin, a marker of iron 
accumulation, is related to advanced fibrosis in patients with 
NAFLD. However, it can also be elevated with systemic 
inflammation. Nevertheless, serum ferritin may be a simple, 
useful marker for obese patients with NAFLD. Further 
studies should confirm the role of iron overload and the 
meaning of hyperferritinemia in patients with chronic liver 
diseases, including NAFLD.
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